H. Lee Moffitt Cancer Center & Research Institute Chief Participates in Clinical Trial Resulting in FDA Approval of New Label for Myelodysplastic Therapy VIDAZA

TAMPA, Fla.--(BUSINESS WIRE)--The Moffitt Cancer Center announced today that Dr. Alan List, Physician-in-Chief, was one of the key investigators in a VIDAZA (azacitidine) clinical trial (AZA-001) whose results the U.S. Food & Drug Administration (FDA) has approved to add to the drug’s label. In May 2004, VIDAZA was the first drug approved by the FDA for the treatment of MDS.